The cheapest way to get tirzepatide
Ranked by published figure, labeled by gate. The cheapest number and the number you can actually get are usually two different routes.
As of August 31, 2026:
Ranked by the dollar figure each route publishes — which is not the same as ranked by what you will pay — the routes to tirzepatide in August 2026 are: a commercial plan that covers Zepbound with Lilly’s savings card (reported as low as $25 a month; insurance-gated, reported only); the Medicare GLP-1 Bridge for eligible Part D enrollees (reported $50 a month, KwikPen only, through December 31, 2027; eligibility-gated, reported only); compounded tirzepatide telehealth (verified from $125 per month on a 12-month plan, billed as a $1,500 prepayment, or $169 true month-to-month); LillyDirect self-pay vials (verified $299–$449 per month by dose); and brand-name Zepbound through a telehealth membership such as Ro, where Lilly’s pricing applies plus the membership (modeled at about $4,977 for a year). The two cheapest routes are gated and reported-only; the verified routes are the compounded rankings and the brand self-pay ladders on this site. A route’s published figure is a starting point, not a quote.
The routes, in order of the figure each one publishes
The order below is the published dollar figure, lowest first — and the first thing to know is that the figures are not like-for-like: the cheapest routes are gated by insurance or eligibility and carried here as reported, not verified. The verified routes are the ones this site exists to rank.
1. Commercial insurance that covers Zepbound + the savings card
Reported as low as $25 a month. Lilly publishes a savings-card price reported to bring a covered commercial prescription to as low as $25 for a 1–3 month fill (annual cap applies), and a non-covered commercial prescription of single-dose Zepbound pens to a reported $499 per month. The card is reported to exclude anyone on Medicare, Medicaid, TRICARE or other government coverage. Reported manufacturer terms, not verified first-party by us; eligibility and caps are set by Lilly and change without notice.
2. Medicare GLP-1 Bridge (eligible Part D enrollees)
Reported $50 a month, KwikPen only. Since July 1, 2026, eligible Medicare Part D enrollees are reported to pay a $50 monthly copay for the Zepbound KwikPen under the CMS GLP-1 Bridge demonstration, reported to run through December 31, 2027 with prior authorization required. Reported eligibility: BMI 35 or higher; or 30 or higher with chronic kidney disease, HFpEF or uncontrolled hypertension; or 27 or higher with prediabetes or established cardiovascular disease. Reported exclusions: Zepbound vials and single-dose pens are not covered, and the $50 does not count toward the Part D deductible or the annual out-of-pocket cap. Details: Medicare GLP-1 coverage.
3. Compounded tirzepatide telehealth
Verified from $125/mo on a plan; $169/mo month-to-month. The verified market: 20 first-party-verified providers, month-to-month range $157–$399 (median $299). Commitment rates and month-to-month rates are different purchases. Rankings: cheapest compounded tirzepatide. Compounded tirzepatide is not an FDA-approved product.
4. Brand-name Zepbound, self-pay via LillyDirect vials
Verified $299–$449/mo by dose. Lilly’s Self Pay Journey conditions apply; missing the refill window is the expensive mistake (regular prices $499–$699 apply). Modeled year about $4,938. Detail: Zepbound self-pay price.
5. Brand-name Zepbound through a telehealth membership
Lilly pricing + membership; modeled about $4,977/yr. The membership buys the prescriber and the workflow; the medication price is Lilly’s. Rows for these programs live in the brand table of the cost page.
Definitions used on this page
Questions this page answers
What is the cheapest way to get tirzepatide?
Ranked by the dollar figure each route publishes — which is not the same as ranked by what you will pay — the routes to tirzepatide in August 2026 are: a commercial plan that covers Zepbound with Lilly’s savings card (reported as low as $25 a month; insurance-gated, reported only); the Medicare GLP-1 Bridge for eligible Part D enrollees (reported $50 a month, KwikPen only, through December 31, 2027; eligibility-gated, reported only); compounded tirzepatide telehealth (verified from $125 per month on a 12-month plan, billed as a $1,500 prepayment, or $169 true month-to-month); LillyDirect self-pay vials (verified $299–$449 per month by dose); and brand-name Zepbound through a telehealth membership such as Ro, where Lilly’s pricing applies plus the membership (modeled at about $4,977 for a year). The two cheapest routes are gated and reported-only; the verified routes are the compounded rankings and the brand self-pay ladders on this site. A route’s published figure is a starting point, not a quote.
Why are the insurance and Medicare figures labeled “reported”?
Because our verification standard is a first-party check of a purchasable published price, and copay programs are gated by coverage and eligibility that we cannot verify for any given reader. They are carried like grade-D rows: named, attributed, never counted as verified.